Menu
© 2019 All rights reserved.
TMC Life Sciences Berhad Co. No.: 200301021989 (624409-A)
Aged 67, Malaysian
Dato’ Sri Mohd Mokhtar Bin Mohd Shariff was appointed to the Board on 25 January 2019.
He holds a Bachelor of Law (Hons) degree, a Master of Business Administration, Certificate of Legal Practice, and was called to the Malaysian Bar in September 2019.
Prior to joining the Board, Dato’ Sri Mohd Mokhtar had an illustrious career serving the Royal Malaysia Police from 3 July 1977 to 22 May 2018. Throughout his tenure, he held various key senior positions, including Director of Special Branch, Director of Narcotics Crime Investigation Department, Chief Police Officer of Johor, Deputy Chief Police Officer of Pahang, and Head of Special Branch Kuala Lumpur. In addition, he also served in the Embassy of Malaysia in Bangkok, Thailand.
Dato’ Sri Mohd Mokhtar has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed
by the relevant regulatory bodies during the financial year under review. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia, other than his position as independent and non-executive director of MY E.G. Services Berhad, South Malaysia Industries Berhad and Pacific & Orient Bhd.
Aged 69, Malaysian
Mr. Barry Kan Kheong Ng was appointed to the Board on 2 June 2015 and re-designated to Executive Vice Chairman on 10 November 2023. He holds a Degree in Business Administration from the Royal Melbourne Institute of Technology. With nearly 30 years of experience in the automotive industry, he has demonstrated exceptional expertise in managing renowned global brands throughout his career with Wearnes Automotive, a prestigious regional dealership headquartered in Singapore. Before joining Wearnes Automotive, he spent 7 years at the Port Authority of Singapore.
During his tenure as General Manager at Malayan Motors, a division of Wearnes Automotive Pte. Ltd., Mr. Barry Kan oversaw the franchises of Rolls Royce, Bentley, Jaguar, and Volvo Trucks in Singapore. He successfully introduced these brands into new territories such as Brunei, Indonesia, Taiwan, and Thailand. In addition to his strategic management role, he took interest in Customer Relationship Management and Aftersales operations, resulting in a high level of clientele retention for the luxury automotive brands.
As the Managing Director of the Prestige Division of Wearnes Automotive, Mr. Barry Kan played a pivotal role in acquiring new brands, including Bugatti, Land Rover, and McLaren. He also served as the key representative for the company’s esteemed high-society clientele, including Captains of Industry and members of Royal families within the region.
When presented with the exciting opportunity to develop the integrated automotive hub in Nusajaya, Iskandar Malaysia, Mr. Barry Kan joined Fastrack Autosports (Iskandar) Pte. Ltd., as part of the project’s conceptualisation and execution. Currently, he manages the joint venture company, Fastrack Iskandar Sdn. Bhd., in collaboration with UEM Sunrise Berhad. In addition, Mr. Barry Kan serves as the Chief Executive Officer and Executive Director of Secura Group Limited (Singapore Listed).
Mr. Barry Kan is also a director of Wellington College International Regional Management Pte. Ltd., which serves as the master agreement holder for the Wellington College International schools in Singapore, Indonesia, and Malaysia.
Mr. Barry Kan has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed
by the relevant regulatory bodies during the financial year under review. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia.
Aged 41, Singaporean
Dr. Heng Jun Li Melvin was appointed to the Board on 26 January 2023 and re-designated to Acting Group Chief Executive Officer of the Company on 29 January 2024. He is currently the Executive Director and Group Chief Executive
Officer of Thomson Medical Group Limited, Singapore. He leads and manages the Group and works actively with the Board and Management to set the overall strategic direction focused on driving business operations and growth of the Group.
Dr. Heng is a physician and healthcare executive with more than 10 years of experience in hospital management, primary and specialist clinics, teleradiology, MedTech and aeromedical evacuations. Dr. Heng is a medical advisor and investor in several MedTech companies such as Mesh Bio Pte. Ltd. and Global Health Byte Pte. Ltd. (now UNO Technologies Pte. Ltd.).
From 2016 to 2018, Dr. Heng served as an advisor to the Ministry of Health in the Primary Care IT sub-committee for National Electronic Health Records and GP Connect in Singapore. Before joining Thomson Medical Group Limited, Dr. Heng was with Gleneagles Hospital where he held various leadership positions including Chief Executive Officer and Chief Operating Officer.
From 2009 to 2015, Dr. Heng was a medical doctor with the National Health Service (United Kingdom) and Tan Tock Seng Hospital. After leaving the public service, Dr. Heng co-founded an aeromedical evacuation company (Global
Medical Concierge Pte. Ltd.) and was also an equity partner at OneCare Medical Pte. Ltd., a chain of primary care clinics.
Dr. Heng was awarded the Public Service Medal (COVID-19) by the Singapore Government in 2023.
Dr. Heng graduated from the St George’s Hospital Medical School in London with a Bachelor of Medicine and Bachelor of Surgery. He holds a Master of Business Administration from the Frankfurt School of Finance and Management and has a Graduate Diploma in Occupational Medicine from the National University of Singapore.
Dr. Heng has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year under review. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia.
Aged 50, Malaysian
Ms. June Leong Lai Ling was appointed to the Board on 1 July 2022. She holds a Master’s in Business Administration from Peking University in Beijing and a BSc in Engineering with Management from King’s College London in the United Kingdom.
Currently, Ms. June Leong serves as an Independent Director of Thomson Medical Group Limited (“TMGL”) and is a member of the Audit and Risk Committee of TMGL. In addition to her role at TMGL, she is the Chief Executive Officer of Alpha Goal International (“Alpha Goal”), a dedicated single-family office that makes investments worldwide across various asset classes, including a portfolio of listed equities, hedge funds, and private equity funds.
Before joining Alpha Goal, Ms. June Leong held the position of Executive Director at China International Capital Corporation. She embarked on her career in 1995 as an Analyst in Morgan Stanley’s investment banking division
in Singapore. Subsequently, she became an Executive Director at Goldman Sachs Private Wealth Management, based in Hong Kong, where she served Hong Kong, China, and Southeast Asian clients from February 2006 to
October 2008.
Ms. June Leong has no family relationship with any Director and/or major shareholder of the Company. She has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed
by the relevant regulatory bodies during the financial year under review. She has no conflict of interest with the Company. She does not hold any directorship in other public companies and listed issuers in Malaysia.
Aged 56, Malaysian
Ms. Mazrina Binti Arifin was appointed to the Board on 19 May 2023. She qualified as a Certified Chartered Accountant from Chartered Association of Certified Accountants in England and BSc of Science in Accounting from University of Hull in United Kingdom.
Ms. Mazrina Binti Arifin brings a diverse range of experience to the Board. She was attached to Arthur Andersen Tax Services Sdn. Bhd. from 1995 to 1998, where she served as a Senior Tax Consultant. Following her tenure at Arthur Andersen, she ventured into entrepreneurship and founded Under6ers, Child Enrichment Centres, in Kuala Lumpur and Selangor from 2001 to 2009.
In 2010, Ms. Mazrina assumed the role of Finance Director for Springboard 4 Malaysia Sdn. Bhd. and Springboard 4 Asia Ltd. (Labuan), where she played a key role in financial management and oversight until 2015 and is part of the initial team member of the education recruitment business into Cambodia and Vietnam.
Since 2015, Ms. Mazrina has held the position of Finance Director at the Institute for Democracy and Economic Affairs (IDEAS) Berhad, a tax approved charitable organisation and director of IDEAS Autism Centres in Rawang and Nilai. Ms Mazrina holds Finance Director position at IDEAS Research and Policy Berhad, an independent think tank. Her expertise in finance contributes to the strategic direction and financial governance of these organisations.
Furthermore, Ms. Mazrina served as a Senior Independent Non-Executive Director of Hup Seng Industries Berhad from 2000 to 2022, Chairman of Nominating Committee and
Senior member of Audit Committee during the tenure; where she provided valuable insights and guidance as an independent director. Ms. Mazrina has also been appointed as member of audit committee of Usains Holdings Sdn. Bhd. (the corporate arm of Universiti Sains Malaysia
– USM) from August 2024.
Ms. Mazrina has a proven track record in financial
management and a deep understanding of the business landscape. Her diverse experiences in taxation, entrepreneurship, and non-profit organisations making her a valuable member of the Board.
Ms. Mazrina has no family relationship with any Director and/or major shareholder of the Company. She has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed
by the relevant regulatory bodies during the financial year under review. She has no conflict of interest with the Company. She does not hold any directorship in other public companies and listed issuers in Malaysia.
Aged 50, Male, Malaysian
Dato’ Mohd Sheridan Bin Ramli was appointed to the Board on 15 July 2023.
Dato’ Sheridan specialises in the fundraising process of different and various financial instruments such as equities and debt for various corporates and institutions. He sits on the Investment Committee panel of Urusharta Jamaah Sdn. Bhd., a wholly-owned company of the Malaysian Ministry of Finance. Dato’ Sheridan was the Deputy President/Chief Executive Officer of K & N Kenanga Holdings Bhd from 2006 to 2010.
Dato’ Sheridan holds a Masters of Business Administration from the University of Nottingham, United Kingdom.
Dato’ Sheridan has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed
by the relevant regulatory bodies during the financial year under review. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia.
Aged 71, Malaysian
Non-Independent Non-Executive Chairman
Professor Emeritus Dato’ Dr. Khalid Bin Abdul Kadir was appointed to the Board on 7 October 2004. He graduated with first-class honours in B.Med. Sc. (1973) and a first class honours in MBBS from Monash University, Australia in 1975 and PhD in 1982. He was awarded the FRACP (Australia) and FRCP’s from Edinburgh, Glasgow, Ireland and London and the Honorary Fellowship of the American College of Physician in June 2008 and is a Fellow of the Academy of Science Malaysia.
Professor Emeritus Dato’ Dr. Khalid started his career as a lecturer at Universiti Kebangsaan Malaysia (“UKM”) in 1982, promoted to Associate Professor in 1984, Head of Department of Medicine in 1985, Dean of the Medical Faculty and Professor in 1990. In 1997-2000, he was Director of the new Hospital Universiti Kebangsaan Malaysia (“HUKM”) with the task of building up HUKM. Upon his retirement in 2004, he was awarded the title of Professor Emeritus.
He then joined Monash University as Professor of Medicine and started the Tan Sri Jeffery Cheah Clinical School in Johor.
He was one of the pioneers of the Company and Thomson Hospitals (formerly known as Tropicana Medical Centre) and is currently the consultant Endocrinologist.
He was in the Malaysia Medical Council from 1986 to 2001, President of the Persatuan Diabetes Malaysia from 1985 to 1990, President of the Malaysia Endocrine Society from 1995 to 2001, Member of Council, International Diabetes Federation from 2001 to 2002, and Master of The Academy of Medicine of Malaysia from 2006 to 2008.
He is active in research and has published more than 310 papers in international and national peer reviewed journals. Professor Emeritus Dato’ Dr. Khalid Bin Abdul Kadir was conferred The National Science Award in 1997, The Asia Pacific Nutrition Award in 1996 and The Merdeka Award in 2008, and delivered The Tunku Abdul Rahman Oration, Academy Medicine Malaysia 2010, and the Gold Medal for outstanding services to Malaysian Medical Association May 2016.
Professor Emeritus Dato’ Dr. Khalid Bin Abdul Kadir has no family relationship with any Director and/or major shareholder of the Company. He has no convictions of any offences within the past five (5) years and has no public sanctions and/or penalties imposed by the relevant regulatory bodies during the financial year. He has no conflict of interest with the Company. He does not hold any directorship in other public companies and listed issuers in Malaysia.